Bionomics gains after All Ordinaries rebalance

By Dylan Bushell-Embling
Thursday, 08 March, 2012

Shares in Bionomics (ASX:BNO) have been climbing since the company was added to the S&P All Ordinaries Index.

On Friday Standard & Poor's announced the March quarter rebalance of its ASX indices, including Bionomics' inclusion into the All Ordinaries list of the 500 largest companies on the ASX.

Bionomics (ASX:BNO) shares grew 3.37% on Monday and a further 8.7% on Friday in heavy trading relative to the month so far.

The shares were trading flat at $0.51 as of 11am on Thursday, giving the company a current market capitalisation of around $175.84 million. This compares to a 52-week high of $0.77 per share, and a 52-week low of $0.355.

On Tuesday, the company allocated 30,000 shares to employees, priced between $0.24 and $0.38, under the company's Employee Share Option Plan (ESOP). The company now has 344.9 million shares and 10.5 million unlisted ESOP options on issue.

Adelaide-based Bionomics is developing potential treatments for cancer, multiple sclerosis and anxiety.

Cancer candidate BNC105 is in phase II trials as a treatment for renal cancer and mesothelioma, and the company is also exploring its potential to treat ovarian cancers and all solid tumours.

The compound BNC210 is in phase Ib trials as a treatment for anxiety and depression, while MS treatment candidate KV1.3 is at the pre-clinical stage.

Last month, Bionomics entered the international stage for a patent application covering a method of improving memory in Alzheimer's sufferers.

Related News

A targeted treatment option for psoriasis

New research from MedUni Vienna paves the way for the development of a therapy that not only...

Maternal cannabis use puts kids at risk of behavioural problems

Children exposed to their mother's cannabis use during pregnancy and after birth are three...

Over-the-counter pain relievers may improve concussion recovery

People who take over-the-counter pain relievers after a concussion may recover faster than those...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd